This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NanoDOX 1% doxycycline monohydrate hydrogel
Description: NanoDOX 1% doxycycline monohydrate hydrogel is a topical formulation of doxycycline utilizing Nanotherapeutics' proprietary particle stabilization technology. It is intended for direct contact with the wound and is applied to the entire surface of the wound bed. A secondary dressing, such as gauze or a non-adhering dressing, is used to cover the hydrogel and wound.
The molecular environment of chronic inflammatory diseases, like diabetic foot ulcers, contains abnormally high levels of pro-inflammatory cytokines (TNF-a and IL-1ß) and abnormally high levels of proteases (matrix metalloproteinase [MMPs] and neutrophil elastase), which are theorized to prevent normal wound healing. Doxycycline is an antibiotic that is an inhibitor of high levels of active proteases, including matrix metalloproteinases. Topical treatment of diabetic ulcers with a molecule that reduces inflammation and proteases activity could promote healing by reducing the destruction of endogenous growth factors, receptors, and extra cellular matrix proteins that are essential for wound healing.
Additional information available to subscribers only: